Ghosh R, Tabrizi SJ (2018) Huntington disease. Handb Clin Neurol, vol 147, Elsevier, pp 255–78. https://doi.org/10.1016/B978-0-444-63233-3.00017-8

Fields E, Vaughan E, Tripu D, Lim I, Shrout K, Conway J et al (2021) Gene targeting techniques for huntington’s disease. Ageing Res Rev 70:101385. https://doi.org/10.1016/j.arr.2021.101385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR et al (2015) Huntington disease. Nat Rev Dis Primer 1:15005. https://doi.org/10.1038/nrdp.2015.5

Article  Google Scholar 

Lee JK, Conrad A, Epping E, Mathews K, Magnotta V, Dawson JD et al (2018) Effect of Trinucleotide Repeats in the Huntington’s Gene on Intelligence. EBioMedicine 31:47–53 https://doi.org/10.1016/j.ebiom.2018.03.031

Article  PubMed  PubMed Central  Google Scholar 

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ (2017) Genetics of Huntington’s disease. In van den Heuvel MAHA, Ross CA (eds), Handbook of Clinical Neurology (vol 144, pp 3–14). Elsevier. https://doi.org/10.1016/B978-0-12-801893-4.00001-6

Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M, on behalf of an International Huntington’s Disease Collaborative Group (2004) A new model for prediction of the age of onset and penetrance for huntington’s disease based on CAG length. Clin Genet 65:267–277. https://doi.org/10.1111/j.1399-0004.2004.00241.x

Article  CAS  PubMed  Google Scholar 

Nasir J, Floresco SB, O’Kusky JR, Diewert VM, Richman JM, Zeisler J et al (1995) Targeted disruption of the huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811–823. https://doi.org/10.1016/0092-8674(95)90542-1

Article  CAS  PubMed  Google Scholar 

Barros LF, Porras OH, Bittner CX (2005) Why glucose transport in the brain matters for PET. Trends Neurosci 28:117–119. https://doi.org/10.1016/j.tins.2005.01.002

Article  CAS  PubMed  Google Scholar 

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA et al (2012) Sustained therapeutic reversal of huntington’s disease by transient repression of Huntingtin synthesis. Neuron 74:1031–1044. https://doi.org/10.1016/j.neuron.2012.05.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao A, Vasilyev N, Kaushik A, Duan W, Serganov A (2020) Principles of RNA and nucleotide discrimination by the RNA processing enzyme RppH. Nucleic Acids Res 48:3776–3788. https://doi.org/10.1093/nar/gkaa024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J-M, Wheeler VC, Chao MJ, Vonsattel JPG, Pinto RM, Lucente D et al (2015) Identification of genetic factors that modify clinical onset of huntington’s disease. Cell 162:516–526. https://doi.org/10.1016/j.cell.2015.07.003

Article  CAS  Google Scholar 

Lee J-M, Correia K, Loupe J, Kim K-H, Barker D, Hong EP et al (2019) CAG repeat not polyglutamine length determines timing of huntington’s disease onset. Cell 178:887–900e14. https://doi.org/10.1016/j.cell.2019.06.036

Article  CAS  Google Scholar 

Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E et al (2018) Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nat Rev Drug Discov 17:660–688. https://doi.org/10.1038/nrd.2018.109

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suryavanshi K, Sharma AK, Murti Y, Kumari V, Shanker Shukla K, Kulshreshtha M (2024) Molecular pathways and treatment updates on huntington’s disease withspecial preference to juvenile phase: A comprehensive review. New Emir Med J 05:e02506882276317. https://doi.org/10.2174/0102506882276317240111103545

Article  Google Scholar 

Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98. https://doi.org/10.1016/S1474-4422(10)70245-3

Article  CAS  PubMed  Google Scholar 

Harding RJ, Tong Y (2018) Proteostasis in huntington’s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin 39:754–769. https://doi.org/10.1038/aps.2018.11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattaneo E, Zuccato C, Tartari M (2005) Normal Huntingtin function: an alternative approach to huntington’s disease. Nat Rev Neurosci 6:919–930. https://doi.org/10.1038/nrn1806

Article  CAS  PubMed  Google Scholar 

Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89:910–926. https://doi.org/10.1016/j.neuron.2016.02.003

Article  CAS  PubMed  Google Scholar 

Bulaklak K, Gersbach CA (2020) The once and future gene therapy. Nat Commun 11:5820. https://doi.org/10.1038/s41467-020-19530-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Controlled Release 235:34–47. https://doi.org/10.1016/j.jconrel.2016.05.044

Article  CAS  Google Scholar 

Jurcau A (2022) Molecular pathophysiological mechanisms in huntington’s disease. Biomedicines 10:1432. https://doi.org/10.3390/biomedicines10061432

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puhl DL, D’Amato AR, Gilbert RJ (2019) Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull 150:216–230. https://doi.org/10.1016/j.brainresbull.2019.05.024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ris MM, Deitrich RA, Von Wartburg JP (1975) Inhibition of aldehyde reductase isoenzymes in human and rat brain. Biochem Pharmacol 24:1865–1869. https://doi.org/10.1016/0006-2952(75)90405-0

Article  CAS  PubMed  Google Scholar 

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA et al (2019) Targeting Huntingtin expression in patients with huntington’s disease. N Engl J Med 380:2307–2316. https://doi.org/10.1056/NEJMoa1900907

Article  CAS  PubMed  Google Scholar 

Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91:2076–2080. https://doi.org/10.1073/pnas.91.6.2076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evers MM, Miniarikova J, Juhas S, Vallès A, Bohuslavova B, Juhasova J et al (2018) AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant Huntingtin Lowering in a huntington’s disease minipig model. Mol Ther 26:2163–2177. https://doi.org/10.1016/j.ymthe.2018.06.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavazza A, Hendel A, Bak RO, Rio P, Güell M, Lainšček D et al (2023) Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi. Mol Ther Nucleic Acids. 34:102066 https://doi.org/10.1016/j.omtn.2023.102066

Komatsu H (2021) Innovative therapeutic approaches for huntington’s disease: from nucleic acids to GPCR-Targeting small molecules. Front Cell Neurosci 15:785703. https://doi.org/10.3389/fncel.2021.785703

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391:806–811. https://doi.org/10.1038/35888

Article  CAS  PubMed  Google Scholar 

Bartel DP, MicroRNAs (2004) Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)00045-5